Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma, hormone maintenance therapy may significantly improve survival, according to a new study from researchers at The University of Texas MD Anderson Cancer Center.
Postmenopausal estrogen-based hormone therapy lasting longer than ten years was associated with a decreased risk of Alzheimer's disease in a large study carried out at the University of Eastern Finland.
Taking one-fourth the standard dose of a widely used drug for prostate cancer with a low-fat breakfast can be as effective - and four times less expensive - as taking the standard dose as recommended: on an empty stomach.
Only about 35 percent of precancerous breast lesions morph into cancer if untreated, but physicians cannot identify which lesions are potentially dangerous.
New data presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) demonstrate that analyzing tumor biology with the Oncotype DX test can identify patients unlikely to benefit from chemotherapy prior to breast cancer surgery (neoadjuvant setting) and guide treatment decisions without compromising outcomes.
Building on earlier clinical trials, UCLA researchers have confirmed that the "breakthrough" drug palbociclib when used in combination with the traditional hormonal therapy letrozole delays progression of advanced breast cancer significantly and without the harsh side effects seen in some women prescribed letrozole alone.
Women who undergo hormone therapy for menopausal symptoms such as hot flashes can not only increase bone mass, but also can improve bone structure, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
The current method of treating prostate cancer involves identifying gene defects, which could help with the diagnosis of cancer and the development of individualised cancer treatments for patients.
Painful sex in women after cancer treatment is relatively common, often treatable and needs to be addressed by medical providers, a UC Davis oncologist and researcher suggests.
In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack.
The American Thoracic Society and the Japanese Respiratory Society have published new clinical practice guidelines for the diagnosis and management of lymphangioleiomyomatosis (LAM), a rare lung disease that primarily affects women of child-bearing age.
A new study by investigators at Brigham and Women's Hospital has found that a rise in prostate-specific antigen (PSA) levels in healthy men who have previously been treated for prostate cancer is significantly associated with a 1.6-fold increased risk of death.
Women and men often show marked differences as regards mental illnesses. In order to learn more about this phenomenon, a project supported by the Austrian Science Fund FWF explored how opposite-sex hormonal therapy applied to transgender individuals influences the brain.
Researchers from Case Western Reserve University are teaming with industry and other academics to develop a quick and inexpensive test to predict which women with ER+ breast cancer need chemotherapy and which need only the more tolerable hormonal therapy.
Published in JAMA Oncology, Principal Investigator of Vall d´Hebron Institute of Oncology´s Translational Genomics Group, Team Leader of translational genomics and targeted therapeutics in solid tumors at the August Pi I Sunyer Biomedical Research Institute, and Head of Medical Oncology at the Hospital Clínic in Barcelona, Aleix Prat has led a study showing the intrinsic subtyping of breast cancer by means of a genomic test as the most important prognostic factor in advanced or metastatic hormone-sensitive breast cancer.
Advances that could change gynecologic cancer standard-of-care treatments are the centerpiece of key studies being presented by researchers from The University of Texas MD Anderson Cancer Center's Department of Gynecologic Oncology and Reproductive Medicine at the 2016 Annual Meeting of the American Society of Clinical Oncology.
Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute professor revealed.
Scientists at the Duke Cancer Institute have identified a molecular key that breast cancer cells use to invade bone marrow in mice, where they may be protected from chemotherapy or hormonal therapies that could otherwise eradicate them.
Researchers have shown for the first time that it is possible to use a multi-gene test to identify patients with early breast cancer who can be spared chemotherapy and who will still be alive and well five years after diagnosis.
microRNAs (miRs) are small endogenous noncoding RNA molecules (20–23 nucleotides) derived from imperfectly paired hairpin RNA structures naturally encoded in the genome that act specifically as triggering molecules to control translational repression or mRNA degradation.